Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010044 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPK1 | |
| SCHEMBL27471526 | 0.90 | ALDH1A1 (0.54) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPK1 | |
| SCHEMBL2044509 | 0.90 | ALDH1A1 (0.54) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPK1 | |
| SCHEMBL2044506 | 0.90 | ALDH1A1 (0.54) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPK1 | |
| SCHEMBL22204489 | 0.83 | PDE4A (0.48) | ALDH1A1KMT2AMEN1MAPK1PDE4A | |
| SCHEMBL20801909 | 0.83 | PDE4A (0.48) | ALDH1A1KMT2AMEN1MAPK1PDE4A | |
| SCHEMBL20801960 | 0.83 | PDE4A (0.48) | ALDH1A1KMT2AMEN1MAPK1PDE4A | |
| SCHEMBL428339 | 0.82 | ALDH1A1 (0.60) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPK1 | |
| SCHEMBL20603030 | 0.81 | ESR2 (0.45) | ALDH1A1KMT2ASMN1; SMN2MEN1PDE4A | |
| SCHEMBL20620789 | 0.81 | ESR2 (0.45) | ALDH1A1KMT2ASMN1; SMN2MEN1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4460492-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | (INSERM) Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131677-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-13 | — | — | WO | disclosed |
| EP-2816040-B1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | CENTREXION THERAPEUTICS CORP (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-106083757-B | 2- pi-allyl -1- oxygen -2,3- dihydro -1,2- benzisothiazoles and its preparation method and application | 四川墨凯科技有限公司 | 2018-05-25 | — | — | CN | disclosed |
| US-20160229778-A1 | DIRECT B-ARYLATION OF CARBONYL COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-08-11 | — | — | US | disclosed |
| EP-2379525-B1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INT (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| EP-2816040-A1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20080200525-A1 | PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070123715-A1 | Method of using rhodium quinonoid catalysts | BROWN UNIVERSITY | 2007-05-31 | — | — | US | disclosed |
| US-20070123715-A1 | Method of using rhodium quinonoid catalysts | BROWN UNIVERSITY | 2007-05-31 | — | — | US | disclosed |
| US-20060128670-A1 | Pesticidally active ketone and oxime derivatives | SYNGENTA CROP PROTECTION, INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1638924-A1 | PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES | Syngenta Participations AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113273-A1 | PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-12-29 | — | — | WO | disclosed |
| EP-0940387-B1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998031697-A1 | ARYL C-GLYCOSIDE COMPOUNDS AND SULFATED ESTERS THEREOF | SANKYO COMPANY, LIMITED (JP) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | ALDH1A1 1952/4885KMT2A 4077/4885SMN1; SMN2 4772/4885 |
| US-20070123715-A1 | Method of using rhodium quinonoid catalysts | NQO2, NQO1, RECQL | ALDH1A1 1550/4885KMT2A 2216/4885SMN1; SMN2 3752/4885 |
| US-20060128670-A1 | Pesticidally active ketone and oxime derivatives | CHRM2, CHRM1, DDT | ALDH1A1 1617/4885KMT2A 1883/4885SMN1; SMN2 571/4885 |
| US-20080200525-A1 | PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES | CHRM2, FOXO3, CHRM1 | ALDH1A1 1934/4885KMT2A 2123/4885SMN1; SMN2 624/4885 |
| US-20160229778-A1 | DIRECT B-ARYLATION OF CARBONYL COMPOUNDS | DBH, DDT, CBR3 | ALDH1A1 985/4885KMT2A 592/4885SMN1; SMN2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.